Skip to main content

Table 7 Performance status before or after the administration of alectinib

From: Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study

Patients with CNS-related symptoms in the baseline, n = 28

Before the initiation of alectinib

After the treatment of alectinib

ECOG 0-1

9 (32.1%)

21 (75%)

ECOG ≥ 2

19 (67.9%)

7 (25%)

  1. Fisher exact test: p = 0.003, there was also a steep fall-over in the number of patients with ECOG ≥ 2 points before and after the administration of alectinib
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us